Skip to content

Mirum Pharmaceuticals, Inc.

MIRM

CIK 0001759425 · Pharmaceutical Preparations · Nasdaq

← back to feed
Revenue (TTM)
$532.26M
+54.7% YoY Q1 May 2026
Net Income (TTM)
−$807.79M
+73.4% YoY Q1 May 2026
EPS Diluted (TTM)
−$13.80
+74.6% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-151.6%
Q1 May 2026
Net Margin
-151.8%
Q1 May 2026
Free Cash Flow (TTM)
−$235.05M
Q1 May 2026
Cash
$324.91M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
60.98M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings